Intracranial hemorrhage and liver-associated deaths associated with tipranavir/ritonavir: Review of cases from the FDA's adverse event reporting system

AIDS Patient Care and STDs

Volumn 22, Issue 11, 2008, Pages 843-850

  Chan Tack, Kirk M ^a   Struble, Kimberly A ^a   Birnkrant, Debra B ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; AMPHOTERICIN B; AZITHROMYCIN; BUSPIRONE; CASPOFUNGIN; CITALOPRAM; CLINDAMYCIN; COLESTYRAMINE; CYCLOSPORIN; ENOXAPARIN; ETIRACETAM; FLUCONAZOLE; FOLINIC ACID; GANCICLOVIR; HUMAN GROWTH HORMONE; ITRACONAZOLE; LANSOPRAZOLE; MEGESTROL; MEPREDNISONE; MYCOPHENOLIC ACID; NICARDIPINE; OLANZAPINE; PRAVASTATIN; PROPRANOLOL; PYRIMETHAMINE; RITONAVIR; SALMETEROL; SULFADIAZINE; TIPRANAVIR; UNINDEXED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG APPROVAL; DRUG FATALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; LIVER FAILURE; LIVER TOXICITY; MALE; MORTALITY; PROTON NUCLEAR MAGNETIC RESONANCE; RISK FACTOR;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INTRACRANIAL HEMORRHAGES; LIVER FAILURE; MALE; MIDDLE AGED; PYRIDINES; PYRONES; RITONAVIR; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 56749184934     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2008.0043     Document Type: Article

References (13)

1. Boehringer Ingelheim Pharmaceuticals Inc. Tipranavir (Aptivus) product information. Ridgebury, CT: Boehringer Ingelheim Pharmaceuticals Inc., 2007.
2. Center for Drug Evaluation and Research Approval Package for Tipranavir (NDA 21-814, Approval Date: June 22, 2005) - Medical review.www.fda.gov/cder/ foi/nda/2005/21814_000_Aptivus_medr1.pdf (Last accessed May 11, 2008).
3. Gathe JC Jr, Pierone G, Piliero P, et al. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients. AIDS Res Hum Retroviruses 2007;23:216-223.
4. Kessler DA. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. JAMA 1993;269:2765-2768.
5. Roquer J, Palomeras E, Knobel H, Pou A. Intracerebral haemorrhage in AIDS. Cerebrovasc Dis 1998; 8:222-227.
6. Cole JW, Pinto AN, Hebel R, et al. Acquired immunodeficiency syndrome and the risk of stroke. Stroke 2004;35:51-56.
7. Castrillero EC, Blasco CC. Intracranial hematoma in a patient with AIDS. CMAJ 2005;172:1297.
8. Fultz SL, D Zingmond, Gordon K, et al. Evaluation of Intracranial Hemorrhage in 49,610 HIV-infected Veterans and California Medicaid Recipients [Abstract 819]. Presented at: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, 2007.
9. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354:731-739.
10. Hepatotoxicity Working Group. Concept Paper: Premarketing Evaluation of Drug-Induced Liver Injury www.fda.gov/cder/livertox/ (Last accessed May 11, 2008.)
11. Luthi B, Huttner A, Speck RF, Mueller NJ. Methadone-induced torsades de pointes after stopping lopinavir-ritonavir. Eur J Clin Microbiol Infect Dis 2007;26:367-369.
12. Soriano V, Puoti M, Garcia-Gasco P, et al. Antiretroviral drugs and liver injury. AIDS 2008;22:1-13.
13. Graff J, von Hentig N, Kuczka K, et al. Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo. J Antimicrob Chemother 2008;61:394-399.